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Background: We report the results of a multi-institutional phase II trial that used preop-
erative full-dose gemcitabine and radiotherapy for patients with potentially resectable pan-
creatic carcinoma.
Methods: Patients were treated before surgery with three cycles of full-dose gemcitabine
(1000 mg/m2 intravenously), with radiation during the second cycle (36 Gy in daily 2.4-Gy
fractions). Patients underwent surgery 4 to 6 weeks after the last gemcitabine infusion.
Results: There were 10 men and 10 women, with a median age of 58 years (range, 50–80
years). Nineteen patients (95%) completed therapy without interruption, and one experienced
grade 3 gastrointestinal toxicity. The mean weight loss after therapy was 4.0%. Of 20 patients
taken to surgery, 17 (85%) underwent resections (16 pancreaticoduodenectomies and 1 distal
pancreatectomy). The complication rate was 24%, with an average length of stay of 13.5 days.
There were no operative deaths. Pathologic analysis revealed clear margins in 16 (94%) of 17
and uninvolved lymph nodes in 11 (65%) of 17 specimens. One specimen contained no residual
tumor, and three specimens revealed only microscopic foci of residual disease. With a median
follow-up of 18 months, 7 (41%) of the 17 patients with resected disease are alive with no
recurrence, 3 (18%) are alive with distant metastases, and 7 (41%) have died.
Conclusions: Preoperative gemcitabine/radiotherapy is well tolerated and safe when deliv-
ered in a multi-institutional setting. This protocol had a high rate of subsequent resection, with
acceptable morbidity. The high rate of negative margins and uninvolved nodes suggests a
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significant tumor response. Preliminary survival data are encouraging. This regimen should be
considered in future neoadjuvant trials for pancreatic cancer.
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Recommendations for combined-modality therapy
in patients with potentially resectable pancreatic can-
cer often include the use of 5-fluorouracil (5-FU) with
concurrent radiotherapy.1 This may be delivered in
either the neoadjuvant or the postoperative adjuvant
setting.2,3 Data suggest only a modest benefit associ-
ated with this therapy.4–6 Clinical trials investigating a
variety of gemcitabine-based chemoradiotherapy reg-
imenswere initiated several years ago.These trialswere
based, in part, on the activity of gemcitabine as the
single most effective agent in patients with advanced
pancreatic cancer, preclinical studies that demon-
strated radiosensitization in pancreatic cancer cell
lines, and the need for treatment strategies with greater
efficacy than that provided by 5-FU–based chemora-
diation.7–9 The regimens investigated to date include
gemcitabine dose escalation with conventional radio-
therapy,10,11 gemcitabine dose escalation with rapid
fractionation,12 the addition of gemcitabine to 5-FU
and radiotherapy,13 and full-dose gemcitabine with
radiotherapy directed at the primary tumor alone.14,15
These investigations have been primarily in patients
with unresectable disease, and few patients have been
investigated in multi-institutional phase II trials.
In most of these trials, emphasis was placed on the
delivery of radiotherapy with gemcitabine dose
escalation. We elected to further investigate the use of
full-dose gemcitabine with modified radiotherapy in a
multi-institutional phase II trial that allowed entry of
patients with potentially resectable pancreatic cancer.
Our selection of this regimen was based on experience
gained in phase I trials and recognition that a regi-
men that emphasizes systemic treatment may provide
an advantage over more conventional combined-
modality approaches, considering the systemic nature
of this disease, while still providing adequate local
control through sensitization of a modest radiation
dose. Prior clinical experience indicated that full-dose
gemcitabine requires a reduction of the radiation
dose and modification of the treatment volumes.
Radiation dose escalation in an initial phase I trial
was achieved by increasing the fraction size and
keeping the duration of radiotherapy at 3 weeks.14
The current trial investigated the use of full-dose
gemcitabine before and after a novel chemoradiation
regimen with full doses of gemcitabine delivered with
concurrent radiotherapy (36 Gy in 2.4-Gy fractions
to the primary tumor alone over 3 weeks). The trial
was designed to include patients with clearly unre-
sectable disease and a second cohort of patients with
potentially resectable cancers. The inclusion of pa-
tients with potentially resectable disease was based on
a previous single-institution experience with patients
who underwent surgical resection after full-dose
gemcitabine and concurrent radiotherapy.15
The objectives of this phase II trial were (1) to
evaluate the toxicity associated with this neoadjuvant
regimen in a multi-institutional setting, (2) to deter-
mine radiographic, tumor marker, and pathologic
responses to treatment, (3) to evaluate morbidity and
mortality among patients who undergo resection after
completion of therapy, and (4) to estimate overall
survival in patients treated with this approach. We
now report the results for patients entered onto the
trial with potentially resectable pancreatic cancers.
PATIENTS AND METHODS
Eligibility and Evaluation
Between April 2002 and October 2003, 41 patients
were entered onto this phase II trial from 5 partici-
pating institutions. Twenty patients were determined
to have potentially resectable pancreatic cancers and
make up the study population. Histological or cyto-
logical confirmation of adenocarcinoma of the
pancreas was required. Patients with tumors in the
head, uncinate process, and body or tail of the pan-
creas were eligible. Patients with tumors other than
adenocarcinoma of the pancreas were excluded.
Determination of resectability was based on helical
computed tomography (CT) scan results by using
criteria defined in the National Comprehensive
Cancer Network guidelines for pancreatic cancer.16
In borderline cases, further confirmation of resection
potential with endoscopic ultrasonography or mag-
netic resonance imaging was required. Tumors were
considered potentially resectable in the absence of
extrapancreatic metastases and with no evidence of
arterial encasement of the celiac and superior mes-
enteric arteries or occlusion of the superior mesen-
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teric vein and portal vein confluence. Further eligi-
bility criteria included age ‡18 years, a Zubrod per-
formance status of £2, and adequate hematological,
hepatic, renal, and cardiac function. Pretreatment
evaluation included a complete history and physical
examination, chest radiograph, and CT scan of the
abdomen. Patients with a history of upper abdominal
radiotherapy or chemotherapy were ineligible.
Patients with obstructive jaundice underwent endo-
scopic biliary decompression before beginning treat-
ment. The institutional review board of each
participating institution approved the trial, and
written informed consent was obtained from all
patients before the initiation of therapy.
During the preoperative phase of treatments, pa-
tients underwent regular assessments of body weight
and performance status and routine laboratory stud-
ies. Surgery was planned approximately 6 weeks after
the completion of therapy, and all patients underwent
repeat staging studies to exclude disease progression.
Treatment Regimen
Gemcitabine was administered as a 30-minute
intravenous infusion at a dose of 1000 mg/m2 on
days 1 and 8 of a 21-day cycle before and after a
28 day cycle of gemcitabine (1000 mg/m2 days 1, 8,
and 15) and concurrent radiation. The planned
course of radiation was 36 Gy in 2.4 fractions to
the gross tumor alone on days 1 to 19 (Fig. 1).
Dose adjustments of gemcitabine were made on the
basis of the toxicity experienced, including the
absolute granulocyte count (AGC) and platelet
count, taken on the day of therapy. A full dose was
delivered for AGC ‡1,000 lL and platelets ‡75,000
lL. A 25% dose reduction was given for AGC ‡500
and <1,000 lL and/or platelets between 50,000
and 75,000 lL, and the dose was held for AGC
<500 lL or platelets <50,000 lL. If gemcitabine
was held during combined therapy, radiotherapy
was also held. Treatment was resumed, if delayed,
when toxicity had resolved to grade £2. There was
a 1-week break between cycles and after the com-
pletion of the third cycle. The occurrence of gas-
trointestinal dose-limiting toxicity prompted
discontinuation of radiotherapy and gemcitabine (if
noted on the day of planned infusion). The occur-
rence of toxicities grade ‡3 in other organ systems
prompted discontinuation of therapy while appro-
priate evaluation was performed. Treatment was
not resumed unless recovery to grade <3 toxicity
occurred in £2 weeks.
Three-dimensional radiotreatment planning was
used in all cases. Treatment planning CT was ob-
tained on a helical scanner with both oral and intra-
venous contrast. The gross tumor volume was the
primary tumor identifiable on CT scan. The clinical
target volume was defined as the gross tumor volume
plus .5 cm. The planning target volume was the clin-
ical target volume plus .5 cm for daily patient setup
variation. No prophylactic nodal irradiation was gi-
ven. Treatment planning was performed with the
isocenter calculated at 100% and the 95% line
encompassing 99.5% of the planning target volume.
The spinal cord was limited to a generally accepted
tolerance dose, considering the change in fraction size.
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Gemcitabine: 1000 mg/m2 30 min IV infusion G
36 Gy in 15 fractionsXRT 
FIG. 1. Treatment schema of full-dose gemcitabine (1000 mg/m2) and concurrent radiation (36 Gy in 2.4-Gy fractions). Gemcitabine was
administered on days 1 and 8 of a 21-day cycle before and after a 28-day cycle of gemcitabine on days 1, 8, and 15 and concurrent radiation on
days 1 to 19. XRT, radiotherapy.
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No more than 50% of the combined renal function
was to receive >20 Gy. Generally, a three-field non-
axial beam arrangement (opposed laterals with an
anterior-inferior oblique) was used, as previously de-
scribed.14 Before radiotherapy was initiated, the ori-
ginal CT scans, digital reconstructed radiographs of
the radiotherapy fields, treatment plans, and dose-
volume histograms were centrally reviewed (W.S. and
C.J.M.) and adjusted if necessary.
Assessment of Treatment Responses and Surgical
Outcomes
Radiographical responses were determined by a
comparison of pretreatment CT and presurgical
scans. A partial response was defined as at least a 30%
decrease in the longest diameter of the primary tumor,
taking as a reference the baseline longest diameter. A
complete response was the disappearance of the pri-
mary tumor. Progression was defined as at least a 20%
increase in the longest diameter of the primary tumor
or the appearance of one or more new lesions. Stable
disease was defined as neither a tumor response suf-
ficient to qualify as a partial response nor an increase
sufficient to qualify as progressive disease.
Information regarding surgical therapy after the
completionof the protocol therapy included the type of
operation performed, the duration of the operation,
estimated blood loss, complications, including the 30-
day mortality rate, and the length of stay. Surgical
complications were defined as postoperative problems
that resulted in a longer stay, reoperation, or read-
mission. Designated pathologists at each institution
examined resected specimens, and their review in-
cluded an assessment of the histological treatment re-
sponse, the size of the primary tumor, resection
margins, and lymph node status. Survival was calcu-
lated from the date of treatment initiation to the date of
death or last follow-up. Survival curves were calcu-
lated by using the method of Kaplan and Meier.17
RESULTS
Patient and Primary Tumor Characteristics
Therewere 10male and 10 female patients (Table 1).
The median age was 58 years (range, 50–80 years).
Seventeen cancers originated in the head of the pan-
creas, one tumor involved the head and neck of the
pancreas, and two tumors were located in the body of
the pancreas. The median pretherapy tumor diameter,
measured from the preregistration CT, was 3.0 cm
(range, 1.0–5.0 cm). The treating surgeon determined
the initial assessment of resection potential with sub-
sequent confirmation by the trials surgical principal
investigator (M.S.T.). Fourteen patients were consid-
ered to have clearly resectable disease according to
National Comprehensive Cancer Network guidelines,
and six patients were considered to have borderline
resectable disease secondary to partial venous encase-
ment or tumor abutting either the superior mesenteric
or hepatic arteries.
Chemoradiation Toxicity and Surgical Results
Chemoradiation was delivered on an outpatient
basis in all 20 patients. Nineteen patients (95%) com-
pleted therapy without interruption. One patient
experienced hematological toxicity that necessitated
gemcitabine dose reduction in each of the first two
chemotherapy cycles. This included grade 3
neutropenia on day 8 of the first cycle and grade 3
neutropenia on day 15 of the second cycle. There were
no incidences of significant thrombocytopenia. One
patient was treated with erythropoietin for anemia and
required a subsequent reduction in the gemcitabine
dose because of weight loss. No patient experienced
nonhematological toxicity that warranted dose
reduction during chemotherapy alone. One patient
experienced grade 3 gastrointestinal toxicity during the
combined chemoradiation phase of treatments that
caused a 1-week delay in treatment. The mean weight
loss after therapy was 4%. All 20 patients completed
the planned course of chemoradiation (36 Gy). All
patients underwent operationwithin 6weeks of the last
gemcitabine infusion (Table 1).
At the time of exploration, two patients were found
to have hepatic metastases, and one patient had par-
tial encasement of the hepatic artery with soft tissue
infiltration around the celiac axis. Seventeen patients
(85%) underwent pancreatic resections (Table 2).
TABLE 1. Clinical characteristics of patients who received
neoadjuvant gemcitabine and radiotherapy
Variable Data
Median age, y (range) 58 (50–80)
Male/female 10/10
Tumor location
Head or uncinate process 18
Body/tail 2
Pretreatment tumor size (cm)
Median 3.0
Range 1.0–5.0
Full course of therapy completed 20/20
Hospitalizations 0/20
Mean weight loss after therapy (%) 4
Surgery within 6 weeks of last infusion 20/20
NEOADJUVANT GEMCITABINE/RT IN PANCREATIC CANCER 153
Ann. Surg. Oncol. Vol. 13, No. 2, 2006
Fifteen patients underwent a standard pancreatico-
duodenectomy, one patient had a pyloric-preserving
Whipple procedure, and one patient had a distal
pancreatectomy and splenectomy. Five (31%) of the
16 patients who underwent pancreaticoduodenectomy
required combined vascular resection and recon-
struction. The mean operative time for the Whipple
procedures was 7.5 hours (range, 5–10.5 hours), and
the mean estimated blood loss for those patients was
768 mL (range, 250–2200 mL). The complication rate
was 24%, with a median length of stay of 13.5 days
(range, 7–47 days) in all patients who underwent
resection. There were three major postoperative
complications: one patient required re-exploration on
day 1 after surgery for bleeding at the gastrojejunal
anastomosis, one patient required re-exploration for
delayed gastric emptying and revision of the gastro-
jejunal anastomosis, and a third patient required re-
admission for percutaneous drainage of a liver
abscess. There were no operative deaths.
Response
The response to treatment was determined by
comparisons of pretreatment and posttherapy radio-
graphic changes and CA-19.9 levels (Table 3). Re-
sected specimens were examined to determine the
estimated degree of pathologic response, tumor stage,
and margin status. Evaluation for disease status by
helical CT 4 to 6 weeks after completion of the last
cycle of gemcitabine showed stable disease in 16 pa-
tients (80%) and partial response in 3 patients (15%).
One patient had a questionable development of he-
patic metastases. Sixteen patients had a ‡50%
reduction in CA-19.9 levels after therapy. The median
CA-19.9 value before treatment initiation was 359 U
(range, 15–9951 U). The median CA-19.9 value after
neoadjuvant treatment and before surgery was 35 U
(range, not detectable to 1254 U; P < .05).
The pathologic findings in the 17 patients who
underwent resection are listed in Table 3. The median
tumor size was 3.0 cm. One specimen contained no
residual tumor, and three specimens revealed only
microscopic foci of residual disease (Fig. 2). Surgical
resection margins revealed no microscopic evidence
of cancer in 16 (94%) of the 17 resected specimens.
The regional lymph nodes in 11 (65%) of 17 patients
were uninvolved by metastatic disease.
Patient Outcomes and Recurrence Patterns
The median follow-up for the entire cohort was 18
months (range, 11.5–30 months). The median overall
survival and 2-year survival rate for the 17 patients
treated with preoperative therapy and surgical resec-
tion were 26 months and 61%, respectively (Fig. 3). Of
the patients who underwent resection, 10 developed
recurrent disease at amedian timeof 8months from the
operation (range, 3–16.5 months). Sites of recurrence
were distant metastases in eight patients and locore-
gional disease in two patients. Seven patients (41%)
remain alive with no evidence of recurrent disease, and
among the four patients with either a complete path-
ologic response (one patient) or only scattered residual
microscopic foci of disease (three patients), three re-
main alive with no evidence of disease at 14, 23.5, and
24 months from surgery.
DISCUSSION
Despite significant advances in preoperative stag-
ing and surgical resection for localized pancreatic
cancer, most patients are not cured by pancreatico-
duodenectomy alone. The treatment strategy of
TABLE 2. Results of surgery after neoadjuvant therapy
Variable Data
Resection rate 17/20 (85%)
Standard pancreaticoduodenectomy 15
Pyloric-preserving 1
Distal pancreatectomy and splenectomy 1




Estimated blood loss (mL)
Mean 768
Range 250–2200
Length of stay (d)
Median 13.5
Range 7–47
Major complication rate (%) 24
Mortality rate (%) 0
TABLE 3. Response to therapy
Variable Data
Radiographic responses by CT comparisons
Stable disease 16 (80%)
Partial response 3 (15%)
Possible progression 1 (5%)
CA 19-9 levels, U, median (range)
Before treatment 359 (15–9951)
After treatment 35 (ND–1254)*
Pathologic findings and responses
Median tumor size 3.0 cm
Treatment effect noted 17/17/ resected
>90% tumor destructiona 4/17 (24%)
Resection margins negative (R0) 16/17 (94%)
Regional nodes negative 11/17 (65%)
CT, computed tomography; ND, not detectable.
a One complete partial response.
* P < .05.
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combined-modality therapy in pancreatic cancer is
based in large part on data from serial Gastrointes-
tinal Tumor Study Group trials that investigated
5-FU–based chemoradiotherapy.1,18,19 A benefit of
combined-modality therapy was observed compared
with radiotherapy alone in patients with unresectable
disease and compared with observations in patients
who had undergone surgical resection. These studies
provided the basis for clinical trials investigating
adjuvant and neoadjuvant approaches in patients
with localized pancreatic cancer for the next 20 years.
Potential advantages of neoadjuvant therapy in
pancreatic cancer patients have been well described
and include the possibility of delivering full courses of
chemotherapy and radiation without the potential
delays caused by surgical complications and pro-
longed recovery times. A second potential advantage
of neoadjuvant therapy is the avoidance of surgery in
patients with rapidly progressive disease found on
repeat staging studies after chemoradiation and be-
fore surgery.20,21 Concerns regarding the safety of
pancreaticoduodenectomy after chemoradiation have
not been manifested in prior trials with either in-
creased complication or mortality rates.20–23 Unfor-
tunately, clinical trials using 5-FU–based
neoadjuvant chemoradiation have not resulted in
significantly improved survival rates.20–23 The use of
gemcitabine with concurrent radiation represents an
alternative approach to improve outcomes in patients
with pancreatic cancer.
Gemcitabine is a deoxycytidine analogue (2¢,2¢-
difluoro-2¢-deoxycitidine or dFdCyd) and has been
shown to provide a survival advantage over 5-FU in
patients with locally advanced (unresectable) or
metastatic pancreatic cancer, as well as symptomatic
relief in patients with metastatic pancreatic cancer in
FIG. 2. Pretreatment cytological analysis and postsurgical
pathologic specimen in a patient with a complete pathologic
response after neoadjuvant chemoradiation. (A) Pretreatment
aspiration cytological specimen demonstrating malignant
glandular cells arising in the head of the pancreas. (B) Surgical
specimen demonstrating posttherapy changes consistent with
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FIG. 3. Kaplan-Meier overall survival curve
for patients treated with neoadjuvant gem-
citabine/radiotherapy followed by pancreatic
resection (n = 17). The median follow-up
was 18 months (range, 11.5–30 months).
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whom prior treatment with 5-FU has failed.7,24 In
addition, laboratory studies have demonstrated po-
tent radiosensitization with gemcitabine in human
cancer cell lines, including pancreatic cancer cell
lines.8,9 Since 1996, phase I trials have investigated
the use of gemcitabine with concurrent radiotherapy
in patients with locally advanced pancreatic cancer.
Initial trials attempted to determine the maximum
tolerable dose of gemcitabine when it was delivered
once weekly, concurrent with a relatively conven-
tional course of radiotherapy (50.4 Gy in 1.8-Gy
fractions).18 Considering the clinical benefit associ-
ated with the use of gemcitabine as a systemic agent,
an alternative strategy used a standard dose of
gemcitabine (1000 mg/m2/week) and investigated the
tolerable radiation dose that could be delivered to
the primary tumor (without inclusion of the regional
lymph node basins).14 The goal of this approach was
to maximize the systemic drug effect while providing
local control through sensitization of a modest
radiation dose. Escalation of the radiation dose was
achieved by increasing the fraction size, thus keeping
the duration of radiation at 3 weeks. After com-
pletion of this phase I trial, McGinn et al.14 con-
cluded that 36 Gy in 2.4-Gy fractions was the
recommended dose for phase II investigation. Tox-
icity data from this trial and the prior trials of
gemcitabine dose escalation with more conventional
radiotherapy suggested that the volume of normal
tissue radiated in gemcitabine-based chemotherapy
regimens was the most critical consideration.10–14
Therefore, radiation fields in this study were planned
with three-dimensional radiotherapy planning and
covered only the gross target volume with a 1-cm
margin (i.e., there was no elective nodal radiother-
apy). The current trial design consisted of a 21-day
cycle of gemcitabine (1000 mg/m2 days 1 and 8)
before and after a 28-day cycle of gemcitabine (1000
mg/m2 days 1, 8, and 15) delivered with concurrent
radiotherapy (36 Gy in 2.4-Gy fractions to the pri-
mary tumor alone, days 1–19). Finally, data from a
single-institution study at the University of Michi-
gan demonstrated the feasibility of surgical resection
after gemcitabine and radiation with acceptable
toxicity and no operative deaths and served as the
rationale to use this regimen in the neoadjuvant
setting.15
The primary goal of this trial was to determine
whether the single-institution experience that indi-
cated the safety and potential efficacy of this novel
chemoradiotherapy regimen could be demonstrated
in a multi-institutional setting. Evaluation of acute
toxicity demonstrated that this regimen was remark-
ably well tolerated. All 20 patients completed a full
course of therapy. Only one patient experienced
grade 3 gastrointestinal toxicity that necessitated a
delay in treatment, none required hospitalization for
acute toxicity, and all went to surgery within 6 weeks
of the last chemotherapy infusion. These results
compare favorably to those from previous neoadju-
vant trials, which demonstrated hospitalization rates
between 9% and 43% and dose-limiting toxicity rates
between 20% and 50%.3,20–23 Explanations for this
acceptable toxicity profile include extremely strict
inclusion criteria of patients with acceptable perfor-
mance status and tumors that were truly likely to be
resectable and, most importantly, the modification in
radiation treatment fields. Prophylactic nodal irradi-
ation was excluded, thereby minimizing the large
volume of healthy tissue treated.
Investigators at M. D. Anderson Cancer Center
reported significant gastrointestinal toxicity (43%)
when weekly gemcitabine was delivered at doses ‡350
mg/m2 with concurrent rapid fractionation (30 Gy in
3-Gy fractions). Treatment volumes reported with
rapid fractionation included the primary tumor
with a 3- to 5-cm margin, as well as the porta hepatis
and celiac lymph nodes.12 Relatively larger radiation
fields were also used in a phase I Eastern Cooperative
Oncology Group trial that examined the use of
gemcitabine with concurrent protracted venous
infusion of 5-FU and radiation (59.4 Gy in 1.8-Gy
fractions) in locally advanced disease.13 Despite low
doses of gemcitabine (50 and 100 mg/m2), significant
gastrointestinal toxicity was seen in three of seven
patients, and radiation field size was implicated in the
toxicity encountered. Results from this trial indicate
improved tolerance and decreased toxicity with full-
dose gemcitabine when appropriate modifications in
the delivery of radiation are made.
The current trial also confirmed the favorable re-
sponse rates of this regimen demonstrated in the
University of Michigan experience reported by Am-
mori et al.15 In that study, pathologic evaluation re-
vealed no evidence of malignancy in the surgical
margins or regional lymph nodes in six of the nine
patients who underwent resection after preoperative
gemcitabine and radiation. Two patients had <10%
viable-appearing tumor cells present, and one patient
had destruction of 50% to 90% of tumors cells seen.
The remaining patients all had some degree of tumor
response, and the degree of fibrosis was considered to
be extensive in six of the nine patients. A significant
local treatment response was also seen in the preop-
erative gemcitabine/radiation trial at M. D. Ander-
son, with 58% of resected specimens showing at least
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50% tumor cell kill.25 There were also two pathologic
complete responses—something not seen in any of
their previous 5-FU–based protocols.25 In the current
trial, some degree of treatment response was seen in
each resected specimen, and 4 (24%) of the 17 pa-
tients had >90% tumor destruction, with 1 complete
pathologic response. Three of these patients remain
alive with no evidence of recurrent or metastatic
disease.
Single-institution trials using 5-FU–based neoad-
juvant chemoradiation have reported resection rates
between 53% and 70% for localized pancreatic
cancer.3,20–23 Hoffman et al.22 reported a resection
rate of 45% in a multi-institutional Eastern Coop-
erative Oncology Group trial that examined con-
tinuous infusional 5-FU, mitomycin, and
conventional radiation (50 Gy in 1.8-Gy fractions).
In the M. D. Anderson trial noted previously, the
resection rate with gemcitabine and 30 Gy by using
the rapid fractionation technique was 74%.25 By
using gemcitabine dose-escalation schemes and rel-
atively fixed-dose conventional radiation, Fox Chase
Cancer Center reported a resection rate of 65% in 63
patients variously treated since 1996.26 In the pilot
study of the current regimen performed at the
University of Michigan, the resection rate was
52%.15 The resection rate in the current multi-insti-
tutional trial was 85%. Also notable was the high
rate of margin-negative resections (94%) and unin-
volved lymph nodes (65%). This was especially
encouraging considering that one of the tenets of
this protocol was to limit gastrointestinal toxicity by
foregoing prophylactic regional nodal irradiation. It
seems from these studies that gemcitabine-based
chemoradiation may result in a high rate of suc-
cessful pancreatic resections and may be associated
with a higher rate of margin-negative, node-negative
resections than 5-FU–based chemoradiation or sur-
gery alone. In addition, standard parameters of
surgical quality, such as operative times, estimated
blood loss, length of stay, and morbidity and mor-
tality rates, were not appreciably different from
those in previous reports of combined-modality tri-
als in resectable pancreatic cancer; this supports the
safety of this regimen.
In conclusion, this neoadjuvant trial of full-dose
gemcitabine with concurrent radiation was well tol-
erated and safe when delivered in a multi-institutional
setting. This regimen had a high rate of subsequent
resection with acceptable morbidity rates. The high
rate of clear margins, uninvolved lymph nodes, and
pathologic responses suggests significant treatment
effects, and preliminary survival data are encourag-
ing. This design has the major advantage of providing
full-dose systemic therapy to patients with early-stage
(resectable) disease. These patients, who are likely to
have the lowest systemic disease burden, may ulti-
mately experience the greatest benefit from a neoad-
juvant combined-modality regimen that emphasizes
systemic therapy and maintains the benefit of local
disease control with reduced risk of treatment-related
toxicity. This novel combination of gemcitabine and
radiotherapy should be considered in future clinical
trials for patients with potentially resectable pancre-
atic cancer.
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